Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy

Table 1 Baseline characteristics data, laboratory tests and clinical outcomes of 104 patients with primary sclerosing cholangitis and ulcerative colitis who underwent colectomy

Patient characteristics1	Total (n = 104)	Patients who continued follow-up or developed primary endpoints (n = 78)
Baseline characteristics data
Age at colectomy (yr)	43 (30-53)	42 (28-52)
Gender, male	70 (67)	56 (72)
Race, Caucasian	98 (94)	76 (97)
Presence of advanced liver fibrosis at baseline	27 (32)	24 (39)
Mayo risk score at baseline	-0.05 (-0.7, 1.1)	-0.001 (-0.8, 1.4)
BMI (kg/m2)	25 (22.6, 28.6)	24.7 (22, 27.4)
Previous use of immunosuppressive drugs	38 (36.5)	29 (37)
History of receiving ursodeoxycholic acid	33 (31.7)	26 (33.3)
Diabetes mellitus or impaired glucose tolerance	7 (7)	6 (7.6)
History of current smoking	2 (2)	2 (2.6)
Indication for colectomy
Severe colonic inflammation	51 (49)	37 (47)
Colonic dysplasia	44 (42)	36 (46)
Bowel perforation	3 (2.8)	3 (3.8)
Other indications	6 (5.7)	2 (2.6)
Laboratory tests at baseline
ALT (< 40 U/L)	70 (43, 113)	73 (43, 135)
AST (< 40 U/L)	50 (30, 96)	55 (32, 100)
Albumin (g/dL)	3.9 (3.5, 4.2)	3.9 (3.5, 4.2)
Total bilirubin (mg/dL)	0.7 (0.5, 1.5)	0.8 (0.5, 1.9)
Direct bilirubin (mg/dL)	0.2 (0.1, 0.7)	0.3 (0.1, 0.9)
ALP (U/L)	359 (194, 657)	385 (197, 839)
Glucose (mg/dL)	93 (86, 106)	93.5 (86, 107)
Creatinine (mg/dL)	1.0 (0.9, 1.1)	1.0 (0.9, 1.1)
CA 19-9 (normal < 55 U/mL)	17.2 (8.8, 51)	16.8 (8.5, 51)
Platelet (× 109/L)	289 (201, 350)	289 (205, 351)
INR	1 (0.9, 1.1)	1 (0.9, 1.1)
Clinical outcomes at the end of follow-up
Undergoing Ileal pouch-anal anastomosis	78 (75)	58 (74)
Length of hospital stay (d)	7 (6, 11)	8 (5, 12)
New diagnosis of malignancy after colectomy	32 (30.8)	26 (33.4)
Colorectal cancer	19 (18.3)	13 (16.7)
Other malignancy	13 (12.5)	13 (16.7)
Pathological findings
Colonic inflammation	62 (60)	45 (57.7)
Presence of colonic dysplasia	24 (23)	21 (27)
Colon cancer	19 (18.3)	12 (15.4)
Post-operative general complications within 1 mo	36 (34.6)	34 (43.6)
Post-operative liver complications within 1 mo	9 (8.7)2	9 (11.5)
Results of follow-up
All-cause mortality	13 (12.5)	13 (16.7)
Liver transplantation	13 (12.5)	13 (16.7)
Continued follow-up	52 (50)	52 (66.6)
Lost to follow-up	13 (25.0)	-

¹Median (interquartile range; IQR) or n (%);

²Including worsening liver tests (n = 3), liver failure requiring liver transplantation (n = 2), acute cholangitis (n = 3) and right hepatic vein thrombosis with hepatic infarct (n = 1). BMI: Body mass index; ALT: Alanine transaminase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; CA 19-9: Cancer antigen 19-9.